Actimed Therapeutics
Manufacturing · United Kingdom · 1-10 Employees
View Company Info for Free
Overview
Headquarters
The Old Bakehouse Course Rd, Ascot And C...Website
www.actimedtherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Actimed Therapeutics
Headquartered in Berkshire, United Kingdom, Actimed Therapeutics is a clinical stage biopharmaceutical company focused on bringing innovation to the treatment of muscle wasting disorders to transform the care of an underserved and vulnerable patient population. Actimed was founded in 2017 by Stefan Anker and Andrew Coats, two world leading physicians in muscle wasting research.Explore more
Actimed Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Actimed Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Actimed Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Actimed Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check out if Actimed Therapeutics is spiking on competitors!
Check if Actimed Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Actimed Therapeutics
Funding: Get notified immidiatlly once Actimed Therapeutics has new funding data
Product Launch: Get notified when Actimed Therapeutics launches new products
Actimed Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Actimed Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Actimed Therapeutics
Compare insights from companies similar to Actimed Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Actimed Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Actimed Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Actimed Therapeutics.
Actimed Therapeutics financials insights
Gather financial insights about Actimed Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Angel/Seed
$6M
Series A
$12.4M
Actimed Therapeutics Tech Stack
A closer look at the technologies used by Actimed Therapeutics
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
Actimed Therapeutics News & Media
Actimed Therapeutics Announces Important Licensing Agreement with Mankind Pharma
London, UK – 21st Novemeber 2025. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, today announces that it has entered into a licensing agreement with Mankind Pharma Limited (“Mankind”), one of India’s leading innovative pharmaceutical companies and a shareholder in Actimed, granting Mankind exclusive rights to develop and commercialise Actimed’sActimed Therapeutics Further Expands Intellectual Property Portfolio for Lead Compound with New Composition of Matter Patent in Japan
Patent expands IP protection for S-pindolol benzoate (ACM-001.1), reinforcing the global IP position of Actimed with granted patents in all key marketsActimed Therapeutics Enrolls First Patients in Phase 2a PROACT Study Programme to Assess S-pindolol benzoate in Obese Patients During and Post-GLP-1 Agonist Therapy
London, UK – 25 June 2025. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on the treatment of cancer cachexia and other muscle wasting disorders, today announces that the first patients have been enrolled in the Company’s Phase 2a muscle optimisation trial PROACT (Preserving, Restoring, and Optimising (lean mass and muscle) with ACTAs) investigating the use of S-pindolol benzoate in combination with GLP-1 receptor agonists in the managemeActimed Therapeutics Announces New Programme to Investigate Potential Muscle Preservation Effects of S-pindolol Benzoate in Obese Patients Treated with GLP-1 Agonists
London, UK – 20th May 2025. Actimed Therapeutics, a UK-based clinical stage specialty pharmaceutical company focused on the treatment of cancer cachexia and other muscle wasting disorders, today announces the commencement of a new development programme investigating the potential benefits of using S-pindolol benzoate (ACM-001.1) during and post-GLP-1 receptor agonist (GLP-1RA) therapy in the management of obesity and related metabolic conditions.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Actimed Therapeutics
Sign Up For FreeTo access detailed company insights
Headquartered in Berkshire, United Kingdom, Actimed Therapeutics is a clinical stage biopharmaceutical company focused on bringing innovation to the treatment of muscle wasting disorders to transform the care of an underserved and vulnerable patient population. Actimed was founded in 2017 by Stefan Anker and Andrew Coats, two world leading physicia... Read More
